The Tisch Cancer Institute (TCI) Human Immune Monitoring Core Shared Resource Facility (HIMCSRF) provides TCI members access to a comprehensive suite of immune monitoring assays allowing for the quantification of circulating proteins and immune cell characterization, along with spatial organization in tissues to support basic science, clinical, and translational studies. This is achieved by balancing innovation with robust protocols and operating procedures to ensure data quality and reproducibility with dedicated platforms for biospecimen processing and sample management, soluble factor profiling, phenotypic and functional immune cell characterization, immunogenomics, single cell transcriptomics, and multiplexed tissue imaging. The HIMCSRF is comprised of over twenty full time experts who specialize in characterizing immune profiles and responses across a diverse range of disease settings. The HIMC currently supports over 45 federal and foundation funded projects across a diverse range of clinical areas including cancer, and also serves as a central analysis hub for several multi-institutional consortia including the NIH Human Immunology Project Consortium (HIPC). The HIMCSRF is also an NCI-designated Cancer Immune Monitoring and Analysis Center (CIMAC) as part of a U24 consortium funded through the Cancer Moonshot program, and also actively supports 13 industry-sponsored research collaborations. Since its inception in 2011, the HIMCSRF contributed to the TCI?s mission by providing state-of-the-art technologies, project development, consistency, interpretations, and cost-effectiveness to all TCI programs.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA196521-06
Application #
10022661
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
2015-08-01
Project End
2025-07-31
Budget Start
2020-08-01
Budget End
2021-07-31
Support Year
6
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Icahn School of Medicine at Mount Sinai
Department
Type
DUNS #
078861598
City
New York
State
NY
Country
United States
Zip Code
10029
Hu, Liangyuan; Hogan, Joseph W; Mwangi, Ann W et al. (2018) Modeling the causal effect of treatment initiation time on survival: Application to HIV/TB co-infection. Biometrics 74:703-713
Ferrara, James L M; Chaudhry, Mohammed S (2018) GVHD: biology matters. Hematology Am Soc Hematol Educ Program 2018:221-227
Labgaa, Ismail; Villacorta-Martin, Carlos; D'Avola, Delia et al. (2018) A pilot study of ultra-deep targeted sequencing of plasma DNA identifies driver mutations in hepatocellular carcinoma. Oncogene 37:3740-3752
Mascarenhas, J; Virtgaym, E; Stal, M et al. (2018) Outcomes of patients with myelofibrosis treated with compassionate use pacritinib: a sponsor-independent international study. Ann Hematol 97:1369-1374
Wu, Lisa M; Amidi, Ali; Valdimarsdottir, Heiddis et al. (2018) The Effect of Systematic Light Exposure on Sleep in a Mixed Group of Fatigued Cancer Survivors. J Clin Sleep Med 14:31-39
Miller, Albert; Szeinuk, Jaime; Noonan, Curtis W et al. (2018) Libby Amphibole Disease: Pulmonary Function and CT Abnormalities in Vermiculite Miners. J Occup Environ Med 60:167-173
Vuong, Linh T; Iomini, Carlo; Balmer, Sophie et al. (2018) Kinesin-2 and IFT-A act as a complex promoting nuclear localization of ?-catenin during Wnt signalling. Nat Commun 9:5304
Bickell, Nina A; Lin, Jenny J; Abramson, Sarah R et al. (2018) Racial Disparities in Clinically Significant Prostate Cancer Treatment: The Potential Health Information Technology Offers. J Oncol Pract 14:e23-e33
Li, Weiqiang; Middha, Mridu; Bicak, Mesude et al. (2018) Genome-wide Scan Identifies Role for AOX1 in Prostate Cancer Survival. Eur Urol 74:710-719
Nobre, Ana Rita; Entenberg, David; Wang, Yarong et al. (2018) The Different Routes to Metastasis via Hypoxia-Regulated Programs. Trends Cell Biol 28:941-956

Showing the most recent 10 out of 143 publications